Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma

Epidermal growth factor receptor (EGFR) is highly expressed in most of Nasopharyngeal carcinoma (NPC) samples and is associated with poor outcomes. Therefore, targeting EGFR may be a promising strategy to improve patient prognosis. Nimotuzumab is a humanized anti-EGFR monoclonal antibody. Recently,...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Renba, Yang, Liu, Zhu, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482709/
https://www.ncbi.nlm.nih.gov/pubmed/33504193
http://dx.doi.org/10.1177/1073274821989301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482709/
https://www.ncbi.nlm.nih.gov/pubmed/33504193
http://dx.doi.org/10.1177/1073274821989301

Ejemplares similares